Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which promises to provide a more reliable and easier treatment for patients.

An injection of anti-Rh antibodies (widely known by the trade name RhoGAM) given to the mother soon after birth neutralizes any fetal blood cells in their circulation before their immune system ...

Spanish pharma company Grifols' shares up on Brookfield talk Shares in Spanish pharmaceutical company Grifols rose on Wednesday after Canadian fund Brookfield said it was talking with shareholders ...